William Chou

Algemeen Directeur bij PASSAGE BIO, INC.

Vermogen: - $ op 30-04-2024

51 jaar

Consumer Services

Health Technology

Actieve functies van William Chou

Bedrijven	Functie	Begin	Einde
PASSAGE BIO, INC.	Directeur/Bestuurslid	10-10-2022	-
	Algemeen Directeur	10-10-2022	-
	President	-	-

Bedrijven	Functie	Begin	Einde
Aruvant Sciences, Inc. Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.	Algemeen Directeur	19-11-2019	-

Yale School of Management	Masters Business Admin
University of Pittsburgh School of Medicine	Doctorate Degree
Princeton University	Undergraduate Degree

Internationaal

Verenigde Staten

Operationeel

Sectoraal

Consumer Services	4
Health Technology	3

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
PASSAGE BIO, INC.	Health Technology

Bedrijven in privébezit	1
Aruvant Sciences, Inc. Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY.	Health Technology

Bedrijven in privébezit

Health Technology